IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 (GlobeNewswire) – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the following investor conferences in June 2024.
William Blair 44th Annual Growth Stock Conference
Presentation: Wednesday, June 5, at 5:00pm ET
Webcast: https://wsw.com/webcast/blair97/mdxh/1942906
Jefferies Global Healthcare Conference
Presentation: Thursday, June 6, at 1:30pm ET
Webcast: https://wsw.com/webcast/jeff302/mdxh/1846928
Live webcasts of the presentations will be accessible on the Investor page of mdxhealth’s website at https://mdxhealth.com/presentations-events/. Replays will be available for up to 60 days following each event.
About mdxhealth®
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
| mdxhealth This email address is being protected from spambots. You need JavaScript enabled to view it. | |
| LifeSci Advisors (IR & PR) US: +1 518-221-0106 This email address is being protected from spambots. You need JavaScript enabled to view it. |
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

| Last Trade: | US$3.58 |
| Daily Change: | -0.11 -2.98 |
| Daily Volume: | 37,258 |
| Market Cap: | US$177.210M |
November 12, 2025 July 03, 2025 May 14, 2025 February 26, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load